Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan for ischemic digital ulcers in systemic sclerosis
2010-022969-95Phase 3Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic sclerosis (SSc) comparing macitentan with placebo (2 arms). Primary endpoint: Cumulative number of new digital ulcers at Week 16. Started Jan 2011; status: terminated.
02
Drugs
macitentan
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2010-022969-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022969-95.